Abiraterone Tablet
Product Images NDC 82249-010

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone (NDC 82249-010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Abiraterone-chem-structure (Abiraterone Tablets Civicascript Llc 1)

Chemical structure of Abiraterone acetate, illustrating its steroidal framework with a pyridine ring and acetate functional group.*

FDA Label Image

Bl-250mg-120s (Abiraterone Tablets Civicascript Llc 7)

Label for Abiraterone Acetate Tablets USP, 250 mg oral tablets supplied by CivicaScript, LLC. Label indicates handling warnings for women who are or may be pregnant, dosage storage instructions, and a 120-tablet count. Includes a barcode, QR code, and manufacturing information by The Arab Pharmaceuticals Manufacturing Company, Sahab - Jordan.*

FDA Label Image

Figure-1 (Image 01)

A Kaplan-Meier survival curve chart comparing % survival over time to death in months for Abiraterone Acetate versus placebo groups. The chart includes survival percentages on the y-axis and time in months on the x-axis, with survival data counts displayed for both groups at various timepoints up to 21 months. The solid line represents Abiraterone Acetate, and the dashed line represents placebo.*

FDA Label Image

Figure-2 (Image 02)

A survival curve graph comparing the percentage of subjects without death over time in months from randomization for Abiraterone Acetate versus placebo. The x-axis represents months from randomization (0 to 60), and the y-axis shows the percentage of subjects without death (0% to 100%). The graph includes two curves: a solid line for Abiraterone Acetate and a dashed line for placebo, indicating survival differences between the two groups.*

FDA Label Image

Figure-3 (Image 03)

A survival curve chart showing the percentage of subjects without radiographic progression or death over time in months from randomization for a clinical comparison between Abiraterone Acetate and Placebo. The chart uses a solid line for Abiraterone Acetate and a dashed line for Placebo, with subject counts listed at intervals below the x-axis.*

FDA Label Image

Figure-4 (Image 04)

A survival curve chart showing the percentage of subjects without death over months from randomization comparing abiraterone acetate and placebo groups. The x-axis represents months from randomization (0 to 72), and the y-axis shows the percentage survival (0% to 100%). Below the graph, the number of subjects at risk for each group is listed across time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.